{
    "clinical_study": {
        "@rank": "61986", 
        "arm_group": [
            {
                "arm_group_label": "Dapsone Formulation A", 
                "arm_group_type": "Experimental", 
                "description": "Dapsone Formulation A applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks."
            }, 
            {
                "arm_group_label": "Dapsone Formulation B", 
                "arm_group_type": "Experimental", 
                "description": "Dapsone Formulation B applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks."
            }, 
            {
                "arm_group_label": "Dapsone Formulation C", 
                "arm_group_type": "Experimental", 
                "description": "Dapsone Formulation C applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks."
            }, 
            {
                "arm_group_label": "Dapsone 5% Gel", 
                "arm_group_type": "Active Comparator", 
                "description": "Dapsone 5% gel (ACZONE\u00ae) applied twice daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will assess the safety, tolerability, and efficacy of dapsone in subjects with\n      acne vulgaris following 12 weeks of treatment."
        }, 
        "brief_title": "An Extension Study to Assess the Safety, Tolerability, Efficacy, and Treatment Adherence of Dapsone in Acne Vulgaris", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Acne Vulgaris", 
        "condition_browse": {
            "mesh_term": "Acne Vulgaris"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Participation in Allergan study 225678-004\n\n        Exclusion Criteria:\n\n          -  Anticipates the need for surgery or hospitalization during the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "35 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01785836", 
            "org_study_id": "225678-005"
        }, 
        "intervention": [
            {
                "arm_group_label": "Dapsone Formulation A", 
                "description": "Dapsone Formulation A applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.", 
                "intervention_name": "Dapsone Formulation A", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Dapsone Formulation B", 
                "description": "Dapsone Formulation B applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.", 
                "intervention_name": "Dapsone Formulation B", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Dapsone Formulation C", 
                "description": "Dapsone Formulation C applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.", 
                "intervention_name": "Dapsone Formulation C", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Dapsone 5% Gel", 
                "description": "Dapsone 5% gel (ACZONE\u00ae) applied twice daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.", 
                "intervention_name": "Dapsone 5% Gel", 
                "intervention_type": "Drug", 
                "other_name": "ACZONE\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Dapsone"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 22, 2013", 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from Baseline in Inflammatory Lesion Count", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01785836"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from Baseline in Non-Inflammatory Lesion Count", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12"
            }, 
            {
                "measure": "Change from Baseline in Total Lesion Count", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12"
            }, 
            {
                "measure": "Percentage of Subjects With a Global Acne Assessment Score (GAAS) of 0 or 1", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }
        ], 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013", 
        "why_stopped": "Study was never initiated due to company decision. No study subjects were ever enrolled or\n    dosed."
    }
}